title: Priorities for the Priority Review Voucher.
abstract: The U.S. Congress created the priority review voucher program in 2007 to encourage development of drugs for neglected diseases. Under the voucher program, the developer of a drug for a neglected or rare pediatric disease that is approved by the U.S. Food and Drug Administration receives a bonus priority review voucher for another drug. As of 2016, four vouchers have sold for an average price of $200 million. Recent experience with the voucher program indicates strengths and weaknesses of the program, as well as a need for legislative changes.
authors: Duke University, Durham, North Carolina.
authors: David B
authors: DB
authors: Ridley
mesh_terms: D000890:Anti-Infective Agents / Q000592:standards; D017277:Drug Approval / Q000379:methods* / Q000458:organization & administration*; D055808:Drug Discovery / Q000191:economics; D006801:Humans; D058069:Neglected Diseases / Q000188:drug therapy*; D009965:Orphan Drug Production / Q000592:standards; D004364:Pharmaceutical Preparations; D014330:Tropical Medicine; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D000890:Anti-Infective Agents; D004364:Pharmaceutical Preparations